SUPPLEMENT

Q4 2020 — Sales of Key Products/Franchises

Q4 2020PDF · 4 pages211 KB
REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
CONSUMER HEALTH SEGMENT (2,3)
OTC
US 	543	$ 	542 	0.1% 	0.1% 	- 	2,460	$ 	2,010 	22.4% 	22.4% 	-
Intl 	642 	653 	-1.7% 	-2.9% 	1.2% 	2,364 	2,434 	-2.9% 	-1.2% 	-1.7%
WW 	1,185 	1,195 	-0.8% 	-1.5% 	0.7% 	4,824 	4,444 	8.5% 	9.4% 	-0.9%
SKIN HEALTH / BEAUTY
(4)
US 	583 	582 	0.2% 	0.2% 	- 	2,350 	2,392 	-1.7% 	-1.7% 	-
Intl 	594 	568 	4.6% 	5.0% 	-0.4% 	2,100 	2,201 	-4.6% 	-2.3% 	-2.3%
WW 	1,177 	1,150 	2.4% 	2.6% 	-0.2% 	4,450 	4,593 	-3.1% 	-2.0% 	-1.1%
ORAL CARE
US 	173 	159 	8.3% 	8.3% 	- 	683 	621 	9.9% 	9.9% 	-
Intl 	264 	233 	13.5% 	14.5% 	-1.0% 	958 	906 	5.7% 	9.6% 	-3.9%
WW 	437 	393 	11.4% 	12.0% 	-0.6% 	1,641 	1,528 	7.4% 	9.7% 	-2.3%
BABY CARE
US 	97 	85 	14.3% 	14.3% 	- 	376 	362 	3.7% 	3.7% 	-
Intl 	310 	336 	-7.8% 	-3.6% 	-4.2% 	1,141 	1,313 	-13.1% 	-7.3% 	-5.8%
WW 	407 	421 	-3.4% 	0.0% 	-3.4% 	1,517 	1,675 	-9.4% 	-4.9% 	-4.5%
WOMEN'S HEALTH
US 	3 	3 	11.8% 	11.8% 	- 	13 	12 	8.2% 	8.2% 	-
Intl 	234 	250 	-6.5% 	-3.1% 	-3.4% 	888 	974 	-8.8% 	-2.9% 	-5.9%
WW 	237 	253 	-6.3% 	-2.9% 	-3.4% 	901 	986 	-8.6% 	-2.7% 	-5.9%
WOUND CARE / OTHER
US 	110 	98 	11.8% 	11.8% 	- 	480 	441 	8.9% 	8.9% 	-
Intl 	65 	57 	12.4% 	13.0% 	-0.6% 	240 	230 	4.1% 	7.3% 	-3.2%
WW 	175 	155 	12.0% 	12.2% 	-0.2% 	720 	671 	7.2% 	8.3% 	-1.1%
TOTAL CONSUMER HEALTH
US 	1,509 	1,470 	2.7% 	2.7% 	- 	6,362 	5,839 	9.0% 	9.0% 	-
Intl 	2,109 	2,097 	0.5% 	1.5% 	-1.0% 	7,691 	8,059 	-4.6% 	-1.3% 	-3.3%
WW 	3,618	$ 	3,567 	1.4% 	2.0% 	-0.6% 	14,053	$ 	13,898 	1.1% 	3.0% 	-1.9%
See footnotes at end of schedule
% Change	% Change

-- 1 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
PHARMACEUTICAL SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
IMMUNOLOGY
US 	2,845	$ 	2,517 	13.0% 	13.0% 	- 	10,175	$ 	9,641 	5.5% 	5.5% 	-
Intl 	1,261 	1,005 	25.4% 	21.1% 	4.3% 	4,880 	4,309 	13.2% 	14.0% 	-0.8%
WW 	4,105 	3,522 	16.6% 	15.3% 	1.3% 	15,055 	13,950 	7.9% 	8.2% 	-0.3%
REMICADE
US 	656 	755 	-13.1% 	-13.1% 	- 	2,508 	3,079 	-18.5% 	-18.5% 	-
US Exports (6) 25 	68 	-62.4% 	-62.4% 	- 	346 	294 	18.0% 	18.0% 	-
Intl 	220 	212 	3.3% 	2.7% 	0.6% 	893 	1,007 	-11.4% 	-8.6% 	-2.8%
WW 	901 	1,035 	-12.9% 	-13.1% 	0.2% 	3,747 	4,380 	-14.4% 	-13.8% 	-0.6%
SIMPONI / SIMPONI ARIA
US 	315 	302 	4.4% 	4.4% 	- 	1,155 	1,159 	-0.3% 	-0.3% 	-
Intl 	261 	213 	22.9% 	18.8% 	4.1% 	1,088 	1,029 	5.8% 	7.0% 	-1.2%
WW 	576 	515 	12.1% 	10.4% 	1.7% 	2,243 	2,188 	2.6% 	3.1% 	-0.5%
STELARA
US 	1,572 	1,194 	31.6% 	31.6% 	- 	5,240 	4,346 	20.6% 	20.6% 	-
Intl 	672 	506 	32.7% 	27.2% 	5.5% 	2,467 	2,015 	22.4% 	22.2% 	0.2%
WW 	2,244 	1,700 	31.9% 	30.3% 	1.6% 	7,707 	6,361 	21.1% 	21.1% 	0.0%
TREMFYA
US 	276 	199 	39.1% 	39.1% 	- 	926 	764 	21.3% 	21.3% 	-
Intl 	105 	71 	48.1% 	40.0% 	8.1% 	421 	248 	69.9% 	67.9% 	2.0%
WW 	382 	270 	41.5% 	39.3% 	2.2% 	1,347 	1,012 	33.2% 	32.7% 	0.5%
OTHER IMMUNOLOGY
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	2 	2 	-19.7% 	-14.5% 	-5.2% 	11 	10 	6.4% 	12.8% 	-6.4%
WW 	2 	2 	-19.7% 	-14.5% 	-5.2% 	11 	10 	6.4% 	12.8% 	-6.4%
INFECTIOUS DISEASES
US 	470 	435 	7.9% 	7.9% 	- 	1,735 	1,597 	8.6% 	8.6% 	-
Intl 	442 	430 	2.8% 	-2.6% 	5.4% 	1,839 	1,815 	1.3% 	2.2% 	-0.9%
WW 	912 	866 	5.4% 	2.7% 	2.7% 	3,574 	3,413 	4.7% 	5.2% 	-0.5%
EDURANT / rilpivirine
US 	11 	14 	-17.9% 	-17.9% 	- 	44 	50 	-11.2% 	-11.2% 	-
Intl 	236 	209 	13.4% 	6.2% 	7.2% 	920 	812 	13.3% 	11.9% 	1.4%
WW 	248 	222 	11.4% 	4.7% 	6.7% 	964 	861 	11.9% 	10.5% 	1.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 	433 	390 	11.1% 	11.1% 	- 	1,587 	1,422 	11.6% 	11.6% 	-
Intl 	136 	155 	-12.4% 	-17.1% 	4.7% 	597 	689 	-13.4% 	-10.7% 	-2.7%
WW 	569 	544 	4.4% 	3.1% 	1.3% 	2,184 	2,110 	3.5% 	4.4% 	-0.9%
OTHER INFECTIOUS DISEASES
US 	25 	32 	-20.4% 	-20.4% 	- 	104 	126 	-17.6% 	-17.6% 	-
Intl 	71 	67 	5.2% 	3.3% 	1.9% 	323 	315 	2.6% 	5.6% 	-3.0%
WW 	96 	99 	-3.0% 	-4.3% 	1.3% 	427 	441 	-3.2% 	-1.0% 	-2.2%
% Change 	% Change

-- 2 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
NEUROSCIENCE
US 	806 	747 	7.9% 	7.9% 	- 	3,091 	2,919 	5.9% 	5.9% 	-
Intl 	892 	819 	9.0% 	6.2% 	2.8% 	3,457 	3,409 	1.4% 	2.2% 	-0.8%
WW 	1,698 	1,566 	8.5% 	7.0% 	1.5% 	6,548 	6,328 	3.5% 	3.9% 	-0.4%
CONCERTA / Methylphenidate
US 	33 	37 	-9.7% 	-9.7% 	- 	183 	233 	-21.4% 	-21.4% 	-
Intl 	120 	115 	4.2% 	1.4% 	2.8% 	439 	463 	-5.1% 	-4.5% 	-0.6%
WW 	153 	152 	0.9% 	-1.2% 	2.1% 	622 	696 	-10.6% 	-10.2% 	-0.4%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 	610 	564 	8.1% 	8.1% 	- 	2,314 	2,107 	9.8% 	9.8% 	-
Intl 	355 	308 	15.7% 	10.8% 	4.9% 	1,339 	1,224 	9.4% 	9.1% 	0.3%
WW 	965 	871 	10.8% 	9.0% 	1.8% 	3,653 	3,330 	9.7% 	9.6% 	0.1%
RISPERDAL CONSTA
US 	76 	77 	-2.5% 	-2.5% 	- 	296 	314 	-5.9% 	-5.9% 	-
Intl 	92 	82 	11.0% 	7.7% 	3.3% 	346 	374 	-7.5% 	-6.9% 	-0.6%
WW 	167 	160 	4.4% 	2.7% 	1.7% 	642 	688 	-6.8% 	-6.4% 	-0.4%
OTHER NEUROSCIENCE
US 	88 	70 	27.4% 	27.4% 	- 	298 	266 	12.4% 	12.4% 	-
Intl 	326 	314 	3.7% 	3.1% 	0.6% 	1,334 	1,349 	-1.1% 	0.7% 	-1.8%
WW 	414 	383 	8.0% 	7.5% 	0.5% 	1,632 	1,614 	1.1% 	2.6% 	-1.5%
ONCOLOGY
US 	1,469 	1,153 	27.4% 	27.4% 	- 	5,092 	4,299 	18.5% 	18.5% 	-
Intl 	1,965 	1,563 	25.7% 	20.9% 	4.8% 	7,275 	6,393 	13.8% 	14.0% 	-0.2%
WW 	3,434 	2,716 	26.4% 	23.7% 	2.7% 	12,367 	10,692 	15.7% 	15.8% 	-0.1%
DARZALEX
US 	692 	444 	55.6% 	55.6% 	- 	2,232 	1,567 	42.4% 	42.4% 	-
Intl 	561 	385 	45.4% 	41.3% 	4.1% 	1,958 	1,430 	36.9% 	38.0% 	-1.1%
WW 	1,253 	830 	50.9% 	49.0% 	1.9% 	4,190 	2,998 	39.8% 	40.3% 	-0.5%
ERLEADA
US 	176 	103 	70.8% 	70.8% 	- 	583 	297 	96.1% 	96.1% 	-
Intl 	64 	13 	* 	* 	* 	176 	35 	* 	* 	*
WW 	241 	116 	* 	* 	* 	760 	332 	* 	* 	*
IMBRUVICA
US 	492 	392 	25.8% 	25.8% 	- 	1,821 	1,555 	17.1% 	17.1% 	-
Intl 	625 	483 	29.3% 	24.8% 	4.5% 	2,307 	1,856 	24.3% 	25.1% 	-0.8%
WW 	1,117 	875 	27.8% 	25.3% 	2.5% 	4,128 	3,411 	21.0% 	21.5% 	-0.5%
VELCADE
US 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Intl 	97 	115 	-15.2% 	-18.5% 	3.3% 	408 	751 	-45.7% 	-45.8% 	0.1%
WW 	97 	115 	-15.2% 	-18.5% 	3.3% 	408 	751 	-45.7% 	-45.8% 	0.1%
ZYTIGA / abiraterone acetate
US 	89 	194 	-54.3% 	-54.3% 	- 	373 	810 	-54.0% 	-54.0% 	-
Intl 	533 	483 	10.2% 	4.3% 	5.9% 	2,097 	1,985 	5.6% 	4.7% 	0.9%
WW 	622 	677 	-8.3% 	-12.5% 	4.2% 	2,470 	2,795 	-11.6% 	-12.3% 	0.7%
OTHER ONCOLOGY
US 	20 	19 	2.6% 	2.6% 	- 	83 	70 	19.2% 	19.2% 	-
Intl 	86 	84 	1.5% 	-2.1% 	3.6% 	330 	336 	-1.9% 	-1.4% 	-0.5%
WW 	105 	104 	1.7% 	-1.2% 	2.9% 	413 	407 	1.7% 	2.2% 	-0.5%
PULMONARY HYPERTENSION
US 	592 	388 	52.5% 	52.5% 	- 	2,133 	1,684 	26.6% 	26.6% 	-
Intl 	273 	235 	16.8% 	12.5% 	4.3% 	1,015 	939 	8.2% 	8.0% 	0.2%
WW 	865 	623 	39.0% 	37.4% 	1.6% 	3,148 	2,623 	20.0% 	20.0% 	0.0%
OPSUMIT
US 	279 	185 	52.1% 	52.1% 	- 	1,008 	766 	31.7% 	31.7% 	-
Intl 	173 	143 	21.2% 	16.9% 	4.3% 	631 	562 	12.3% 	12.3% 	0.0%
WW 	452 	326 	38.6% 	36.7% 	1.9% 	1,639 	1,327 	23.5% 	23.5% 	0.0%
UPTRAVI
US 	263 	178 	48.2% 	48.2% 	- 	955 	714 	33.8% 	33.8% 	-
Intl 	38 	30 	25.5% 	20.1% 	5.4% 	138 	105 	30.9% 	30.5% 	0.4%
WW 	301 	208 	44.9% 	44.1% 	0.8% 	1,093 	819 	33.5% 	33.4% 	0.1%
OTHER PULMONARY HYPERTENSION
US 	49 	26 	84.9% 	84.9% 	- 	169 	205 	-17.6% 	-17.6% 	-
Intl 	63 	62 	2.4% 	-1.2% 	3.6% 	247 	272 	-9.2% 	-9.4% 	0.2%
WW 	112 	88 	26.6% 	24.1% 	2.5% 	416 	476 	-12.8% 	-12.9% 	0.1%
CARDIOVASCULAR / METABOLISM / OTHER
US 	935 	930 	0.6% 	0.6% 	- 	3,509 	3,734 	-6.0% 	-6.0% 	-
Intl 	317 	327 	-2.6% 	-5.4% 	2.8% 	1,369 	1,458 	-6.1% 	-4.8% 	-1.3%
WW 	1,253 	1,256 	-0.2% 	-1.0% 	0.8% 	4,878 	5,192 	-6.0% 	-5.7% 	-0.3%
XARELTO
US 	629 	609 	3.1% 	3.1% 	- 	2,345 	2,313 	1.4% 	1.4% 	-
Intl 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
WW 	629 	609 	3.1% 	3.1% 	- 	2,345 	2,313 	1.4% 	1.4% 	-
INVOKANA / INVOKAMET
US 	159 	125 	27.7% 	27.7% 	- 	564 	536 	5.2% 	5.2% 	-
Intl 	58 	52 	11.5% 	8.9% 	2.6% 	231 	199 	16.3% 	17.6% 	-1.3%
WW 	217 	177 	22.9% 	22.1% 	0.8% 	795 	735 	8.2% 	8.6% 	-0.4%
PROCRIT / EPREX
US 	62 	118 	-46.9% 	-46.9% 	- 	277 	505 	-45.1% 	-45.1% 	-
Intl 	66 	65 	2.0% 	-1.1% 	3.1% 	274 	285 	-3.8% 	-3.6% 	-0.2%
WW 	129 	183 	-29.5% 	-30.6% 	1.1% 	552 	790 	-30.2% 	-30.1% 	-0.1%
OTHER
US 	85 	78 	9.4% 	9.4% 	- 	323 	380 	-15.1% 	-15.1% 	-
Intl 	194 	209 	-7.6% 	-10.3% 	2.7% 	864 	974 	-11.3% 	-9.7% 	-1.6%
WW 	278 	286 	-3.0% 	-5.0% 	2.0% 	1,186 	1,353 	-12.4% 	-11.2% 	-1.2%
TOTAL PHARMACEUTICAL
US 	7,116 	6,169 	15.3% 	15.3% 	- 	25,735 	23,874 	7.8% 	7.8% 	-
Intl 	5,152 	4,379 	17.7% 	13.5% 	4.2% 	19,837 	18,324 	8.3% 	8.8% 	-0.5%
WW 	12,268	$ 	10,548 	16.3% 	14.6% 	1.7% 	45,572	$ 	42,198 	8.0% 	8.2% 	-0.2%
See footnotes at end of schedule
% Change 	% Change

-- 3 of 4 --

REPORTED SALES vs. PRIOR PERIOD ($MM) 	REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER 	TWELVE MONTHS
MEDICAL DEVICES SEGMENT (2,5) 2020 	2019 	Reported 	Operational (1) Currency 	2020 	2019 	Reported 	Operational (1) Currency
INTERVENTIONAL SOLUTIONS
US 	433	$ 	377 	14.8% 	14.8% 	- 	1,452 	1,443 	0.6% 	0.6% 	-
Intl 	460 	398 	15.7% 	10.8% 	4.9% 	1,594 	1,554 	2.6% 	2.0% 	0.6%
WW 	893 	774 	15.3% 	12.8% 	2.5% 	3,046 	2,997 	1.6% 	1.3% 	0.3%
ORTHOPAEDICS
US 	1,352 	1,369 	-1.3% 	-1.3% 	- 	4,779 	5,319 	-10.2% 	-10.2% 	-
Intl 	839 	904 	-7.3% 	-11.3% 	4.0% 	2,984 	3,520 	-15.2% 	-15.4% 	0.2%
WW 	2,191 	2,273 	-3.7% 	-5.3% 	1.6% 	7,763 	8,839 	-12.2% 	-12.3% 	0.1%
HIPS
US 	229 	230 	-0.7% 	-0.7% 	- 	793 	863 	-8.2% 	-8.2% 	-
Intl 	143 	147 	-2.2% 	-5.8% 	3.6% 	487 	575 	-15.3% 	-15.1% 	-0.2%
WW 	372 	377 	-1.3% 	-2.7% 	1.4% 	1,280 	1,438 	-11.0% 	-11.0% 	0.0%
KNEES
US 	216 	239 	-9.5% 	-9.5% 	- 	743 	889 	-16.4% 	-16.4% 	-
Intl 	129 	156 	-17.2% 	-20.6% 	3.4% 	427 	591 	-27.8% 	-28.0% 	0.2%
WW 	345 	395 	-12.5% 	-13.9% 	1.4% 	1,170 	1,480 	-21.0% 	-21.1% 	0.1%
TRAUMA
US 	454 	413 	10.0% 	10.0% 	- 	1,648 	1,652 	-0.2% 	-0.2% 	-
Intl 	268 	273 	-2.0% 	-6.2% 	4.2% 	966 	1,068 	-9.6% 	-9.7% 	0.1%
WW 	722 	686 	5.2% 	3.6% 	1.6% 	2,614 	2,720 	-3.9% 	-3.9% 	0.0%
SPINE, SPORTS & OTHER
(7)
US 	453 	488 	-7.1% 	-7.1% 	- 	1,595 	1,915 	-16.7% 	-16.7% 	-
Intl 	299 	329 	-9.2% 	-13.6% 	4.4% 	1,104 	1,286 	-14.1% 	-14.6% 	0.5%
WW 	752 	817 	-7.9% 	-9.7% 	1.8% 	2,699 	3,201 	-15.7% 	-15.9% 	0.2%
SURGERY
US 	1,002 	961 	4.3% 	4.3% 	- 	3,249 	3,828 	-15.1% 	-15.1% 	-
Intl 	1,427 	1,481 	-3.7% 	-5.9% 	2.2% 	4,983 	5,673 	-12.2% 	-11.2% 	-1.0%
WW 	2,429 	2,442 	-0.5% 	-1.9% 	1.4% 	8,232 	9,501 	-13.4% 	-12.8% 	-0.6%
ADVANCED
US 	456 	428 	6.5% 	6.5% 	- 	1,535 	1,637 	-6.2% 	-6.2% 	-
Intl 	660 	647 	2.1% 	-0.9% 	3.0% 	2,304 	2,458 	-6.2% 	-5.6% 	-0.6%
WW 	1,116 	1,076 	3.8% 	2.0% 	1.8% 	3,839 	4,095 	-6.2% 	-5.8% 	-0.4%
GENERAL
US 	546 	534 	2.5% 	2.5% 	- 	1,714 	2,192 	-21.8% 	-21.8% 	-
Intl 	767 	834 	-8.1% 	-9.8% 	1.7% 	2,679 	3,215 	-16.7% 	-15.5% 	-1.2%
WW 	1,312 	1,366 	-4.0% 	-5.0% 	1.0% 	4,392 	5,406 	-18.8% 	-18.0% 	-0.8%
VISION
US 	397 	428 	-7.3% 	-7.3% 	- 	1,557 	1,794 	-13.2% 	-13.2% 	-
Intl 	679 	713 	-4.7% 	-6.2% 	1.5% 	2,362 	2,830 	-16.5% 	-16.2% 	-0.3%
WW 	1,076 	1,141 	-5.7% 	-6.6% 	0.9% 	3,919 	4,624 	-15.2% 	-15.1% 	-0.1%
CONTACT LENSES / OTHER
US 	289 	311 	-7.4% 	-7.4% 	- 	1,213 	1,304 	-7.0% 	-7.0% 	-
Intl 	507 	522 	-2.7% 	-4.1% 	1.4% 	1,781 	2,088 	-14.7% 	-14.4% 	-0.3%
WW 	796 	833 	-4.4% 	-5.3% 	0.9% 	2,994 	3,392 	-11.7% 	-11.5% 	-0.2%
SURGICAL
US 	108 	117 	-7.1% 	-7.1% 	- 	344 	490 	-29.7% 	-29.7% 	-
Intl 	172 	191 	-10.3% 	-12.0% 	1.7% 	581 	742 	-21.7% 	-21.5% 	-0.2%
WW 	280 	309 	-9.1% 	-10.1% 	1.0% 	925 	1,232 	-24.9% 	-24.7% 	-0.2%
TOTAL MEDICAL DEVICES
US 	3,184 	3,135 	1.5% 	1.5% 	- 	11,036 	12,384 	-10.9% 	-10.9% 	-
Intl 	3,405 	3,497 	-2.6% 	-5.5% 	2.9% 	11,923 	13,579 	-12.2% 	-11.8% 	-0.4%
WW 	6,589	$ 	6,632 	-0.7% 	-2.2% 	1.5% 	22,959	$ 	25,963 	-11.6% 	-11.4% 	-0.2%
* Percentage greater than 100% or not meaningful 	(6) Reported as U.S. sales
(1) Operational growth excludes the effect of translational currency 	(7) Previously referred to as Spine & Other
(2) Unaudited
(3) Previously referred to as Consumer
(4) Previously referred to as Beauty
(5) Certain prior year amounts have been reclassified to conform to current year product disclosures
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely.
% Change 	% Change

-- 4 of 4 --